TDO2 and neoplasm: The conjugate obtained by combining it with irinotecan can improve the tumor immune microenvironment by inhibiting TDO enzyme expression to block kynurenine production and induce HCC cell apoptosis by releasing TDO inhibitors and irinotecan to cause DNA damage [85].